Open AccessPembrolizumab‐axitinib‐induced tumor lysis syndrome in a patient with metastatic renal cancer
Author(s) -
Shah Manan,
Jain Sanjay,
Abe Temidayo,
Surapaneni Phani Keerthi,
Bhatia Kapil
Publication year - 2020
Publication title -
clinical case reports
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.21
H-Index - 9
ISSN - 2050-0904
DOI - 10.1002/ccr3.2737
Subject(s) - medicine , pembrolizumab , tumor lysis syndrome , immunotherapy , nivolumab , axitinib , rasburicase , cancer , complication , intensive care medicine , oncology , chemotherapy , sunitinib
Tumor lysis syndrome is uncommon in solid tumors but with the use of immunotherapy (checkpoint inhibitors) their incidence is increasing. Physicians need to take adequate precautions while treating patients with immunotherapy. The findings of our case report will help improve our current understanding of tumor lysis syndrome specially in solid tumors and will help in developing multidisciplinary treatment and prophylaxis strategies for this uncommon, but potentially fatal complication.